Mirabegron

Description

Mirabegron · CAS 223673-61-8 · C21H24N4O2S. UNII MVR3JL3B2V. European Pharmacopoeia monograph. Solubility: 0.082.

Identification

CAS Registry Number	223673-61-8
PubChem CID	9865528
Molecular formula	C21H24N4O2S
IUPAC name	2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
UNII (FDA)	MVR3JL3B2V
Pharmacopoeial monograph	European Pharmacopoeia monograph

Computed Descriptors

Molecular Weight	396.5
XLogP3	2.1
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	9
Exact Mass	396.16199719
Monoisotopic Mass	396.16199719
Topological Polar Surface Area	129
Heavy Atom Count	28
Formal Charge	0

Physical & Chemical Properties

Solubility	0.082

GHS Hazard Classification

Reported hazard statements	H302 (72.7%), H317 (54.5%), H319 (27.3%), H361 (45.5%), H373 (45.5%), H410 (36.4%)

Documented Uses

• Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with [solifenacin]. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
• Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome. Mirabegron has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
• Take with food. While adults may take mirabegron with or without food, prescribing information recommends that children always co-administer mirabegron with food.
• Compounds that bind to and activate ADRENERGIC BETA-3 RECEPTORS.
• Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.
• Established Pharmacologic Class [EPC] - beta3-Adrenergic Agonist

Synonyms

Mirabegron; 223673-61-8; Myrbetriq; Betanis; Betmiga; YM-178; YM178; MVR3JL3B2V; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide; CHEBI:65349; DTXSID101021648; 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide; 2-(2-Aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide; 4-Thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-; 2-(2-AMINO-1,3-THIAZOL-4-YL)-N-(4-(2-(((2R)-2-HYDROXY-2-PHENYLETHYL)AMINO)ETHYL)PHENYL)ACETAMIDE; mirabegronum

Frequently Asked Questions

What are the CAS number and molecular formula of Mirabegron?

CAS 223673-61-8; molecular formula C21H24N4O2S; molecular weight — g/mol.

What other names is Mirabegron known by?

Mirabegron, 223673-61-8, Myrbetriq, Betanis, Betmiga, YM-178.

Is Mirabegron classified as hazardous?

Hazard statements reported: H302, H317, H319, H361, H373.

Does Mirabegron have a pharmacopoeial monograph?

Yes — a monograph exists in the European Pharmacopoeia (Ph. Eur.).

What are the key physical properties of Mirabegron?

Solubility: 0.082.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.